Tinzaparin

Applied filters

Safety in Lactation: Drugs for thromboembolic disorders

18 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral anticoagulants The coumarin anticoagulants, warfarin…

What factors should be considered when using LMWH to treat venous thromboembolism in patients with high body weight?

14 September 2020Treatment of venous thromboembolism (VTE) in patients with high body weight constitutes a challenge in clinical practice. Adjustments in the dose calculation may be necessary…

Low molecular weight heparins – should treatment doses be used in patients with renal impairment?

25 March 2020Randomised controlled trials evaluating LMWH efficacy and safety have generally excluded patients with severe renal impairment (RI). In contrast to UFH, LMWHs are primarily cleared…

Low molecular weight heparins – should prophylactic doses be used in patients with renal impairment?

23 October 2019This updated Medicines Q & A reviews the evidence available and considers when prophylactic doses of low molecular weight heparins can be used in patients…

What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

4 September 2018This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

ARCHIVED NPSA Alert – Reducing treatment dose errors with low molecular weight heparins 2010

30 July 2010This page forms part of a resource on medication related patient safety alerts issued  by the National Patient Safety Agency (NPSA) between 2002 and 2012…